Coronary disease & ACSSecondary analysis
Future myocardial infarction after an acute coronary syndrome and pharmacogenetic response to dalcetrapib
- Secondary analysis of the Dal-Outcomes and Dal-GenE randomised trials
- prediction index (Cox proportional hazards model)
Authors' conclusion
In the Dal-GenE AA genotype patients, dalcetrapib reduced the rate of MI, independently of those variables.
Study context
- Population
- Acute coronary syndrome (ACS) survivors; index developed in Dal-Outcomes placebo patients, applied in Dal-GenE participants (AA genotype at rs1,967,309 in ADCY9)Dal-GenE
- Participants
- 5,989 survivors
- Comparison
- Dalcetrapib vs placebo, adjusted for an myocardial infarction (MI) prediction index
- Primary endpoint
- Subsequent fatal and non-fatal MI following ACS
Primary result
MI, adjusted for the prediction index
Hazard ratio
0.77
95% CI 0.63–0.94
Dalcetrapib vs Placebo
HR 0.77 (95% CI 0.63–0.94)
As reported in the abstract
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| MI per SD increase in prediction index score (Dal-GenE AA genotype) | 1.92 (1.78–2.08) | |
| 0.512Hazard ratio (log scale) |
Prediction index discrimination (Dal-Outcomes placebo)
- 18 of 36 baseline variables contributed; Harrell's C-index
- 0.72 (95% CI 0.69-0.75)
Original publication
Future myocardial infarction after an acute coronary syndrome and pharmacogenetic response to dalcetrapib. Eur J Prev Cardiol. Published 14 October 2025. doi:10.1093/eurjpc/zwaf661
Summarised from the published abstract; every number is checked against it